Intercept Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
VRXValeant Pharmaceuticals International, Inc. 3.27%29.0714.1%$171.05m
ICLRICON plc 0.93%229.204.2%$156.70m
JAZZJazz Pharmaceuticals Plc 0.57%179.172.2%$142.15m
HZNPHorizon Therapeutics Plc 5.02%92.145.5%$124.53m
CTLTCatalent, Inc. 2.18%102.672.1%$105.63m
BHCBausch Health Cos., Inc. 3.27%29.070.0%$91.68m
SAVACassava Sciences, Inc. 8.31%40.920.0%$55.78m
UTHRUnited Therapeutics Corp. 2.12%197.8714.0%$55.65m
PRGOPerrigo Co. Plc 1.80%45.826.9%$49.71m
BLRXBioLineRx Ltd. 0.00%2.850.8%$38.97m
ARGXargenx SE 4.22%272.300.0%$38.23m
SAGESAGE Therapeutics, Inc. 2.03%70.867.6%$33.60m
PCRXPacira Biosciences, Inc. 1.22%62.219.9%$30.64m
AXSMAxsome Therapeutics, Inc. -2.68%58.421.9%$26.79m
RVMDRevolution Medicines, Inc. 4.07%31.990.0%$23.38m

Company Profile

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.